The Effects of Curcuminoids on Aberrant Crypt Foci in the Human Colon

• Status: Terminated
• Trial end date: 2007-06-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine the effectiveness of curcumin in reducing the number of aberrant crypt foci (ACF) in the colon.

• Phase: N/A
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: University of Medicine and Dentistry of New Jersey
• Treatments: Curcumin; Sulindac

Criteria

Inclusion Criteria:

• Subjects must be eligible for colorectal cancer (CRC) screening/surveillance by current criteria.

• Subjects must have at least 5 ACF on eligibility chromosigmoidoscopy examination.

Exclusion Criteria:

Subjects must not have:

• Alcohol consumption of greater than 2 glasses of wine or beer per day or illicit recreational drug use

• Platelet or coagulation abnormalities, or personal history of a bleeding disorder, including individuals taking warfarin.

• High risk for developing endocarditis (history of endocarditis or rheumatic fever, cardiac valve prostheses, or mitral valve prolapse that requires antibiotic prophylaxis).

• Uncontrolled hypertension, diabetes, or chronic congestive heart failure.

• Renal insufficiency defined as a serum creatinine > 2.5 mg/dl

• History of colorectal surgery with removal of the distal 60 cm of colon or rectum.

• History of other gastrointestinal mucosal epithelial diseases (such as Barrett's esophagus, chronic or recurrent peptic ulcer disease, celiac sprue or other disorders of nutrient absorption).